Rhumbline Advisers Sells 41,621 Shares of Bristol-Myers Squibb Co (BMY)

Rhumbline Advisers reduced its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,633,102 shares of the biopharmaceutical company’s stock after selling 41,621 shares during the quarter. Rhumbline Advisers owned approximately 0.16% of Bristol-Myers Squibb worth $163,463,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of BMY. BlackRock Inc. increased its holdings in Bristol-Myers Squibb by 7.2% during the 2nd quarter. BlackRock Inc. now owns 111,913,559 shares of the biopharmaceutical company’s stock valued at $6,193,296,000 after acquiring an additional 7,517,623 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Bristol-Myers Squibb by 114.5% during the 2nd quarter. Janus Henderson Group PLC now owns 6,922,917 shares of the biopharmaceutical company’s stock valued at $383,119,000 after acquiring an additional 3,695,485 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Bristol-Myers Squibb by 4,455.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 3,416,898 shares of the biopharmaceutical company’s stock valued at $189,091,000 after acquiring an additional 3,341,898 shares in the last quarter. Schroder Investment Management Group increased its holdings in Bristol-Myers Squibb by 419.0% during the 2nd quarter. Schroder Investment Management Group now owns 3,851,748 shares of the biopharmaceutical company’s stock valued at $213,003,000 after acquiring an additional 3,109,664 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in Bristol-Myers Squibb by 44.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 9,460,148 shares of the biopharmaceutical company’s stock valued at $587,287,000 after acquiring an additional 2,903,920 shares in the last quarter. Hedge funds and other institutional investors own 72.60% of the company’s stock.

BMY opened at $53.27 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53. Bristol-Myers Squibb Co has a 1 year low of $46.94 and a 1 year high of $70.05. The company has a market capitalization of $85.84 billion, a P/E ratio of 17.70, a P/E/G ratio of 1.47 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. As a group, equities research analysts anticipate that Bristol-Myers Squibb Co will post 3.88 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, November 1st. Investors of record on Friday, October 5th were given a $0.40 dividend. The ex-dividend date of this dividend was Thursday, October 4th. This represents a $1.60 annualized dividend and a dividend yield of 3.00%. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.

BMY has been the subject of several recent research reports. SunTrust Banks restated a “buy” rating and set a $67.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, July 31st. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 target price for the company in a report on Friday, October 5th. Barclays lifted their price target on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock an “equal weight” rating in a report on Friday, October 12th. Credit Suisse Group set a $61.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Sunday, October 14th. Finally, BMO Capital Markets reiterated a “hold” rating on shares of Bristol-Myers Squibb in a report on Sunday, July 22nd. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $61.62.

COPYRIGHT VIOLATION WARNING: “Rhumbline Advisers Sells 41,621 Shares of Bristol-Myers Squibb Co (BMY)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://sportsperspectives.com/2018/11/16/rhumbline-advisers-sells-41621-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Further Reading: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply